Meaty IPIX PRs like initial RBL results and Fast Track Designation drive the share price up 50-100% with good volume. A PR announcing a multinational phase 2 COVID trial and a favorable peer-reviewed paper would do the same.
The 10Q on the other hand is read by a small fraction of people compared to the PRs. The details in it don't make the news wire. And frankly the last eight or so 10Qs have not exactly been a pleasurable read.
He will issue a glorious PR when is free to. Again, he doesn't write us 33 times about pre-clinical and IND minutia and then leave it at "Trial is scheduled to begin next week" while the stock price falls 30%. You've been here for what? 7,8,9 years? You know that's not how Leo does things.